Welcome to the 13th Tumor Models Summit Boston: Your Must-Attend Preclinical Oncology Meeting of the Summer!
With the preclinical oncology model market projected to hit $5.3 billion by 2030, and analysis tools to characterize models becoming more accessible, it has never been more important for biopharma to gain clarity on best practice in tumor modeling and model selection to achieve clinical translatability.
With these needs in mind, the 13th Tumor Models Summit Boston returns this July to provide an update on tumor model advancements, and how they can complement existing models to increase clinical confidence and relevancy of your candidate; offering a chance to be part of the dialogue advancing bench-to-bedside development for safe and efficacious candidate selection.
With brand new content spanning tumor biology through to toxicology and therapeutic development, here’s what’s exciting this summer:
Free* Attendance for Drug Developers & Researchers: We are here to support your translational studies and pipeline progression, and offer you the opportunity to meet model providers to select the right platforms
Probe the latest advancements in tumor modeling: Delve into best practice to accurately recapitulate the tumor microenvironment across diverse in vitro, 3D, in vivo, ex vivo, and in silico models to achieve more translatable insights to patientsÂ
Access expertise across different modalities: Gain cross-learnings of applying diverse preclinical models to empower the development of ADCs, bispecific T-cell engagers, cell therapies, protein degraders and more as monotherapies and combination therapies to empower your own strategiesÂ
Knowledge-transfer with your peers: You will have the unique opportunity to exchange challenges, inspire solutions with leading industry experts across dedicated speed-networking, panel discussions, roundtable sessions and a new poster competition session to assess the latest modeling innovations over the last 12 monthsÂ
Foster High-Impact Collaborations: Meet and network with carefully selected preclinical CROs offering specialized in vitro, in vivo, and ex vivo models, biomarker assay providers, AI tools and software providers, and imaging platform solutions to advance your workflowsÂ
Hear Why Our Expert Speakers Are Looking Forward to the Summit:
Companies Already Confirmed to be in the Room:
Who Will You Meet?
